GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avantor Inc (NYSE:AVTR) » Definitions » Debt-to-Equity

AVTR (Avantor) Debt-to-Equity : 0.67 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Avantor Debt-to-Equity?

Avantor's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $828 Mil. Avantor's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $3,279 Mil. Avantor's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $6,098 Mil. Avantor's debt to equity for the quarter that ended in Mar. 2025 was 0.67.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Avantor's Debt-to-Equity or its related term are showing as below:

AVTR' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.72   Med: 1.35   Max: 2.21
Current: 0.67

During the past 9 years, the highest Debt-to-Equity Ratio of Avantor was 2.21. The lowest was -2.72. And the median was 1.35.

AVTR's Debt-to-Equity is ranked worse than
79.23% of 698 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs AVTR: 0.67

Avantor Debt-to-Equity Historical Data

The historical data trend for Avantor's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avantor Debt-to-Equity Chart

Avantor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 1.83 1.67 1.30 1.05 0.68

Avantor Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.94 0.89 0.68 0.67

Competitive Comparison of Avantor's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Avantor's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avantor's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avantor's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Avantor's Debt-to-Equity falls into.


;
;

Avantor Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Avantor's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Avantor's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avantor  (NYSE:AVTR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Avantor Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Avantor's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Avantor Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Executives
Gregory L Summe director C/O GLEN CAPITAL PARTNERS LLC, 800 SOUTH STREET, SUITE 160, WALTHAM MA 02453
Joseph R Massaro director 5725 DELPHI DRIVE, TROY MI 48098
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lan Kang director 100 MATSONFORD ROAD, RADNOR PA 19087
James Bramwell officer: EVP, Strategic Partners C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Steven W Eck officer: SVP & Chief Accounting Officer C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Christophe Couturier officer: See Remarks 9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
Benoit Gourdier officer: EVP, Biopharma Production 100 MATSONFORD ROAD, RADNOR PA 19087
Frederic Vanderhaegen officer: EVP, Europe C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer officer: EVP, Chief HR Officer 100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones officer: EVP, Chief Financial Officer C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu officer: EVP, Chief Legal & Compliance C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone officer: EVP, Proprietary Products 974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Gerard Brophy officer: EVP, Biopharma Production C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin officer: EVP, Strategy&Corp Development 100 MATSONFORD ROAD, RADNOR PA 19087